Abstract：
Keratinocytic cancers (KCs), specifically cutaneous squamous cell and basal cell carcinomas, can respond to topical, intralesional, or systemic immunotherapies, but cutaneous adverse events (CAEs) may occur. Understanding these risks, early recognition of these CAEs, and effective treatment may enable patients to continue their anticancer immunotherapies without dose impact. Immune checkpoint inhibitor-related CAEs after KCs can have multiple clinical presentations, with specific observed types including psoriasis and bullous pemphigoid. Cutaneous toxicities can require biopsies to confirm the diagnosis, especially in patients who are not responsive to topical or oral steroids, since the selection of biologic drugs depends on accurate diagnosis. Different types of CAEs from immune checkpoint inhibitors have been associated with different oncologic outcomes in various primary cancer types, and this remains to be determined for KC patients. CAE characterization and management after immune checkpoint inhibitors in KC patients is a rapidly growing field that needs specific and prospective studies.
摘要：
角质细胞癌（KCs），特别是皮肤鳞状细胞癌和基底细胞癌，可以对局部做出反应，病灶内,或全身免疫疗法，但皮肤不良事件（CAE）可能发生。了解这些风险，早期识别这些CAE，和有效的治疗可以使患者继续他们的抗癌免疫疗法没有剂量的影响。KCs后免疫检查点抑制剂相关的CAE可以有多种临床表现，观察到的具体类型包括银屑病和大疱性类天疱疮。皮肤毒性可能需要活检来确认诊断，尤其是对局部或口服类固醇无反应的患者，因为生物药物的选择取决于准确的诊断。来自免疫检查点抑制剂的不同类型的CAE与各种原发性癌症类型的不同肿瘤学结果相关。这仍有待KC患者确定。KC患者免疫检查点抑制剂后的CAE表征和管理是一个快速增长的领域，需要具体和前瞻性研究。
